%0 Journal Article
%T Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities.
%A Yu EM
%A Hwang MW
%A Aragon-Ching JB
%J Res Rep Urol
%V 15
%N 0
%D 2023
%M 38050587
暂无%R 10.2147/RRU.S386517
%X Prostate cancer is the most common non-cutaneous cancer among American men. Multiple mechanisms are involved in tumorigenesis and progression to metastases. While androgen deprivation therapy remains the cornerstone of treatment, progression to castration-resistant disease becomes inevitable. Aberrant pathway activations of PI3K/AKT due to PTEN loss, epithelial-mesenchymal transition pathways, homologous recombination repair, and DNA repair pathway mechanisms of resistance and cross-talk lead to opportunities for therapeutic targeting in metastatic castration-resistant prostate cancer. This review focuses on mechanisms of progression and key trials that evaluate the drugs and combinations that exploit these pathways.